Orris

teach me hepatorenalnsyndrome in complete way

Reading File
Reading File
Searching the Web

hepatorenal syndrome diagnosis treatment 2024 guidance AASLD

Hepatorenal syndrome (HRS) is a broad, clinically important topic. I can teach it in a structured way, then go deep on the part you choose.
Asking for Preferences

Where should we start?

Hepatorenal syndrome (HRS) is a broad, clinically important topic. I can teach it in a structured way, then go deep on the part you choose.
Finding Sources
Finding Sources
Searching PubMed

"hepatorenal syndrome"

Hepatorenal syndrome (HRS): study map

  1. Definition and terminology
    • HRS-AKI, previously called type 1 HRS
    • HRS-NAKI, including HRS-AKD and HRS-CKD
    • Why HRS is a functional renal failure syndrome, not primary kidney destruction
  2. Who develops it
    • Advanced cirrhosis with ascites
    • Acute-on-chronic liver failure
    • Important precipitants: spontaneous bacterial peritonitis, other infection, GI bleeding, overdiuresis, vomiting/diarrhea, large-volume paracentesis without albumin, nephrotoxins
  3. Pathophysiology
    • Portal hypertension causes splanchnic arterial vasodilation
    • Effective arterial blood volume falls despite total-body fluid excess
    • RAAS, sympathetic nervous system, and vasopressin activation cause intense renal vasoconstriction
    • Fall in renal perfusion and GFR leads to HRS
  4. Diagnosis
    • AKI definition in cirrhosis
    • Required HRS-AKI criteria
    • Albumin challenge and withdrawal of diuretics
    • Excluding shock, nephrotoxins, obstruction, glomerular disease, and structural acute tubular injury
  5. Differential diagnosis
    • Prerenal azotemia or volume depletion
    • Acute tubular necrosis
    • Acute interstitial nephritis
    • Glomerulonephritis
    • Postrenal obstruction
    • Cardiorenal dysfunction/cirrhotic cardiomyopathy
  6. Investigations and interpretation
    • Creatinine trends, urine microscopy, urinalysis, urine protein/hematuria
    • Renal ultrasonography
    • Infection work-up including diagnostic paracentesis
    • Limits of urine sodium and FeNa in cirrhosis
    • Role and limits of biomarkers such as NGAL
  7. Management
    • Stabilization and treating the trigger
    • Stop nephrotoxins, reduce or stop diuretics where appropriate
    • Albumin
    • Vasoconstrictors: terlipressin first-line where available, norepinephrine in ICU, and midodrine plus octreotide when alternatives are unavailable
    • Monitoring for ischemia and respiratory failure
  8. Definitive treatment and prognosis
    • Urgent liver-transplant evaluation
    • When renal replacement therapy is a bridge to transplant
    • Limited role of TIPS in selected patients
    • Why response to treatment does not replace transplantation
  9. Prevention
    • Albumin after large-volume paracentesis
    • Albumin with SBP
    • SBP antibiotic prophylaxis in selected high-risk patients
    • Avoiding NSAIDs, inappropriate diuresis, hypotension, and unmonitored nephrotoxins
  10. Exam and bedside approach
  • A diagnostic-treatment algorithm
  • Common viva questions and high-yield comparisons

Big picture

HRS is a severe form of kidney dysfunction in advanced liver disease, especially decompensated cirrhosis with ascites. The kidneys are usually structurally intact early in the process. The main problem is profoundly reduced effective arterial circulation from portal-hypertension-related vasodilation, followed by compensatory neurohormonal activation and renal vasoconstriction.
It is a diagnosis made after actively looking for and correcting other reversible causes of AKI. The practical sequence is: recognize AKI early, identify infection/bleeding/volume loss or drugs, give appropriate albumin-based volume expansion, exclude structural and obstructive kidney disease, then initiate a vasoconstrictor plus albumin if HRS-AKI is established. Liver transplantation is the definitive therapy. Current AASLD guidance emphasizes early recognition, treatment of precipitating events, vasoconstrictor-based therapy, and transplant referral.
A recent evidence update supports terlipressin's ability to improve HRS reversal, but treatment requires careful selection and monitoring, particularly for respiratory adverse events (2025 meta-analysis, PMID 40207491).
Reply with a number, and I’ll teach that section in depth. For the best starting sequence, choose 3: pathophysiology, then 4: diagnosis, then 7: management.

Give me the diagnostic criteria and workup algorithm

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.